GRANULOMATOUS MASTITIS
Clinical trials for GRANULOMATOUS MASTITIS explained in plain language.
Never miss a new study
Get alerted when new GRANULOMATOUS MASTITIS trials appear
Sign up with your email to follow new studies for GRANULOMATOUS MASTITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare breast condition: drug targets stubborn inflammation
Disease control Not yet recruitingThis early-stage trial tests whether tocilizumab, an anti-inflammatory drug, can help women with a rare breast condition called granulomatous lobular mastitis that hasn't improved with steroids. About 31 women aged 20-50 will receive two doses of the drug intravenously. The main …
Matched conditions: GRANULOMATOUS MASTITIS
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New trial aims to end surgery for rare breast disease
Disease control Not yet recruitingThis study tests whether antibiotics or steroids work better for granulomatous lobular mastitis, a rare inflammatory breast condition that mostly affects young women after childbirth. Seventy-two participants will receive either an 8-week course of antibiotics or tapering doses o…
Matched conditions: GRANULOMATOUS MASTITIS
Phase: PHASE1, PHASE2 • Sponsor: All India Institute of Medical Sciences, Bhubaneswar • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New european registry aims to unlock mysteries of rare breast disease
Knowledge-focused Not yet recruitingThis study is creating a European registry for people with idiopathic granulomatous mastitis (IGM), a rare inflammatory breast condition that causes pain, redness, and abscesses. Researchers will collect information from 1,000 participants to better understand symptoms, treatment…
Matched conditions: GRANULOMATOUS MASTITIS
Sponsor: European Breast Cancer Research Association of Surgical Trialists • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC